|Assessment Status||Assessment process complete|
|Indication||For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer.|
|Full pharmacoeconomic assessment commissioned by HSE||03/12/2007|
|NCPE assessment completed||28/01/2008|
|NCPE assessment outcome||Reimbursement recommended.|
Lapatinib could be considered cost-effective in Ireland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.